NASDAQ: OLMA

Olema Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for OLMA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 19:59 UTC.

What Olema Pharmaceuticals, Inc. does

Olema is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer, particularly estrogen receptor-positive disease. The company's lead product candidate, palazestrant, is an orally-available small molecule that works as both a complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in late-stage clinical trials as both a standalone treatment and in combination with other targeted drugs.

Summarized from Olema Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for OLMA are available in Oxford Ledge.
Open OLMA in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-02

2026-09-02CHIEF FINANCIAL OFFICERStock Option (Right to Buy)Award650,000—
2026-07-27DirectorSale-12,500$144.7K
2026-07-27DirectorSale-12,500$146.4K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

FMR LLC12,143,062$151.91M+16.9%
Paradigm Biocapital Advisors LP8,670,576$108.47M+8.1%
Jupiter Topco LLC7,094,413$88.80MNEW

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-08-13Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2026-04-29Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersPrakash RamanEstimatedSEC 8-K →
2026-01-30Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
Yahoo2026-09-14NEG
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha Feed2026-09-10
Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com2026-06-09

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for OLMA and 5,000+ tickers.

Create a free account — keep OLMA

For your agent

GET /api/data?ticker=OLMA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt